Abstract Title

Global, Phase 3, Open-Label, Single-Arm Studies to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg (Triptorelin Mesylate Injection, 11.25 mg) and FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg) in Patients with Advanced Prostate Cancer (KATANA studies).

Time

Thursday, February 13, 2025, from 11:25 AM-12:45 PM PT

Location

Moscone Convention Center West in San Francisco (Level 1, West Hall)

Poster Board Number

M3

Abstract Number

TPS284

Session Title

Trials in Progress Poster Session A: Prostate Cancer